Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Am Fam Physician ; 43(1): 187-94, 1991 Jan.
Article in English | MEDLINE | ID: mdl-1986487

ABSTRACT

Chronic upper lobe cavitary lung disease may be caused by infections, emphysema, cystic fibrosis, lung cancer, sarcoidosis and rheumatologic syndromes. The diagnostic evaluation includes a complete history, a physical examination, a chest radiograph, and sputum examination and culture. In some cases, computed tomographic scanning and biopsy are required.


Subject(s)
Clinical Protocols/standards , Lung Diseases/diagnosis , Adult , Biopsy , Chronic Disease , Diagnosis, Differential , Humans , Lung Diseases/etiology , Lung Diseases/pathology , Male , Physical Examination , Sporotrichosis/blood , Sporotrichosis/complications , Sporotrichosis/immunology , Tomography, X-Ray Computed
4.
Chest ; 97(6): 1482-3, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2347237

ABSTRACT

The first fatal Cunninghamella bertholletiae infection in a clinically immunocompetent host is reported. This case differs from previously reported cases by the lack of extensive vascular invasion and thrombosis.


Subject(s)
Immunocompetence , Lung Diseases, Fungal/microbiology , Mucorales/pathogenicity , Mucormycosis/microbiology , Humans , Male , Middle Aged
5.
Chest ; 97(4): 1014-6, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2323237

ABSTRACT

We present a patient who had chronic, bilateral pleural effusions without evidence of parenchymal, retrocardiac or mediastinal masses. A CAT scan of the abdomen and chest revealed the extension of a large abdominal pseudocyst through the diaphragm into the posterior mediastinum. The pseudocyst resolved with conservative management.


Subject(s)
Mediastinal Cyst/complications , Pleural Effusion/complications , Chronic Disease , Humans , Male , Mediastinal Cyst/diagnostic imaging , Middle Aged , Pancreatic Pseudocyst/complications , Pancreatic Pseudocyst/diagnostic imaging , Pleural Effusion/diagnostic imaging , Tomography, X-Ray Computed
6.
Cancer Res ; 49(16): 4423-6, 1989 Aug 15.
Article in English | MEDLINE | ID: mdl-2787205

ABSTRACT

The side effects associated with recombinant interleukin 2 administration, including systemic hypotension and a vascular leak syndrome, may limit therapy before reaching maximum doses of this innovative and promising treatment for cancer. In an attempt to reverse this hypotension without decreasing cardiac output and systemic oxygen delivery (DO2), we studied several inotropic agents, dobutamine, dopamine, amrinone, CaCl2, and a pure alpha-adrenergic vasoconstrictor, methoxamine. These were administered singly or in combination to sheep with chronically implanted arterial and pulmonary artery catheters following 24 h of 3 x 10(5) units/kg recombinant interleukin 2. Compared to baseline values, 24 h of recombinant interleukin 2 infusion caused a significant increase in cardiac output from 4.4 +/- 0.9 (SD) to 5.0 +/- 0.6 liters/min, a significant fall in systemic vascular resistance (SVR) from 21 +/- 7 to 15 +/- 5 units, a decrease in mean systemic blood pressure (SBP) from 88 +/- 9 to 78 +/- 6 mm Hg, and a decrease in left ventricular stroke work from 51.5 +/- 8 to 49 +/- 6 gram meters (P less than 0.05) without any change in DO2. Dopamine, dobutamine, and CaCl2 returned SBP to baseline values by increasing cardiac output without increasing SVR. Methoxamine increased SBP by increasing SVR, but cardiac output decreased significantly. A combination of 12 micrograms/kg/min of dopamine and 2 to 3 mg of methoxamine infused over 15 min resulted in an increase in SBP, cardiac output, and SVR to baseline values while maintaining DO2 and oxygen consumption (VO2). We suggest that this latter combination would be appropriate for clinical use since it returns physiological parameters to normal.


Subject(s)
Hemodynamics/drug effects , Interleukin-2/adverse effects , Amrinone/pharmacology , Animals , Blood Pressure/drug effects , Calcium Chloride/pharmacology , Cardiac Output/drug effects , Dobutamine/pharmacology , Dopamine/pharmacology , Heart Rate/drug effects , Interleukin-2/therapeutic use , Methoxamine/pharmacology , Recombinant Proteins , Sheep , Stroke Volume/drug effects , Vascular Resistance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...